Twist Bioscience (NASDAQ:TWST – Get Free Report) was upgraded by equities research analysts at Piper Sandler to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.
Several other research analysts have also recently commented on TWST. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Robert W. Baird increased their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a research note on Friday, May 22nd. Guggenheim increased their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, Barclays increased their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.38.
Read Our Latest Analysis on Twist Bioscience
Twist Bioscience Stock Performance
Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the previous year, the company posted ($0.66) EPS. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. Research analysts forecast that Twist Bioscience will post -1.99 EPS for the current fiscal year.
Insider Transactions at Twist Bioscience
In other news, CFO Adam Laponis sold 4,000 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $60.00, for a total value of $240,000.00. Following the transaction, the chief financial officer directly owned 118,694 shares of the company’s stock, valued at $7,121,640. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jan Johannessen sold 12,000 shares of the stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total transaction of $673,440.00. Following the completion of the transaction, the director directly owned 17,754 shares in the company, valued at $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 43,170 shares of company stock valued at $2,418,964. 3.08% of the stock is owned by company insiders.
Hedge Funds Weigh In On Twist Bioscience
Several large investors have recently modified their holdings of the stock. ARK Investment Management LLC raised its position in shares of Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock valued at $239,787,000 after purchasing an additional 832,687 shares during the period. Artisan Partners Limited Partnership raised its position in shares of Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after purchasing an additional 1,349,867 shares during the period. William Blair Investment Management LLC raised its position in shares of Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after purchasing an additional 1,812,146 shares during the period. EdgePoint Investment Group Inc. raised its position in shares of Twist Bioscience by 31.7% in the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after purchasing an additional 1,295,672 shares during the period. Finally, State Street Corp raised its position in shares of Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after purchasing an additional 538,755 shares during the period.
Twist Bioscience Company Profile
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Featured Articles
- Five stocks we like better than Twist Bioscience
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
